Original news and analysis on international IP policy
The Union Cabinet of India has approved ratification of the Nagoya Protocol on Access and Benefit-Sharing, a measure that provides a tool against biopiracy. The 4 October action comes on the eve of the 11th Conference of Parties to the UN Convention on Biological Diversity (CBD).
Ho-Won Kim, the newly appointed commissioner of the Korean Intellectual Property Office (KIPO), discussed his views on KIPO’s major policies in a recent exchange with Intellectual Property Watch. He explained the directions KIPO will take on international cooperation, examination pendency periods, and other issues, such as what the international dispute between Samsung Electronics and Apple means for companies worldwide.
NEW DELHI - In this month, there have been two court orders in India that underscore the complexities underlying the country’s intellectual property regime. Last Friday (14 September), the Chennai-based Intellectual Property Appellate Board (IPAB) which is responsible for hearing appeals on patent applications, rejected a petition by German pharma major Bayer AG, seeking a stay on an order of India’s Controller of Patents granting a compulsory licence (CL) to Indian generic drug maker Natco Pharma Limited, for a drug used to treat liver and kidney cancer.
The Supreme Court of India today did not get to an agenda item involving a challenge to India's patent law by Swiss pharmaceutical company Novartis, and it is now scheduled to come up on 11 September. The case is considered to have potential widespread impact on the production of lower priced generic medicines.
A hearing in a case involving a challenge by Bayer pharmaceutical company of India's compulsory licence aimed at making a cancer drug more affordable is moved to 3 September, public health advocacy group Médecins Sans Frontières (MSF) announced today.
This month, the Indian Supreme Court will hear final arguments in a challenge by the pharmaceutical company Novartis against the Indian Patent Office’s rejection of a patent for the leukemia drug, Glivec. The Court’s ruling will have profound implications for…
The Supreme Court of India has postponed hearing final arguments in a key challenge to India's patent law brought by Swiss pharmaceutical company Novartis.
International trade rules related to intellectual property rights enshrine the notion that there may be cases where exceptions to IP rights are needed by governments, such as sovereign decisions on a nation’s public health. Using those flexibilities could save millions of lives but may mean taking a tough stance in free trade negotiations with bigger trading partners, concluded a meeting of Asian stakeholders this week.
Compulsory licences can provide an efficient way to decrease prices of drugs in developing countries but the conditions of issuance of a licence influence the benefits countries can derive from them, particularly if the countries have a technology gap, according to an economic model presented this week at the World Intellectual Property Organization.
The United States and China will hold early next week what is becoming the largest bilateral programme between their courts in the area of intellectual property adjudication. Set to gather more than a thousand participants, the discussions will largely revolve around patent litigation, according to a top US judge.